These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38990526)

  • 1. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME
    JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in anaplastic thyroid cancer management.
    Hamidi S; Maniakas A
    Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I; Smulever A; Jerkovich F; Pitoia F
    Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
    Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 9. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
    Chen TY; Lorch JH; Wong KS; Barletta JA
    Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
    Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO
    Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
    J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant treatment with lenvatinib and pembrolizumab in a
    Barbaro D; Forleo R; Profilo MA; Lapi P; Giani C; Torregrossa L; Macerola E; Materazzi G
    Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
    J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
    Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
    Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

  • 17. Case report: Complete response of an anaplastic thyroid carcinoma patient with
    Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
    Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
    Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
    Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.